Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer

Breast Cancer Research and Treatment

Volumn 125, Issue 1, 2011, Pages 191-200

  Sedjo, Rebecca L ^a   Devine, Scott ^a  

^a Express Script Inc   (United States)

Author keywords

Anastrozole; Breast cancer; Exemestane; Letrozole; Medication adherence

Indexed keywords

ANASTROZOLE; ANTILIPEMIC AGENT; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER PATIENT; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; COST UTILITY ANALYSIS; DATA BASE; DRUG COST; FEMALE; HEALTH BEHAVIOR; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; TREATMENT DURATION;

ADULT; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DATABASES AS TOPIC; DELIVERY OF HEALTH CARE; DRUG COSTS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INSURANCE, HEALTH; LOGISTIC MODELS; MEDICATION ADHERENCE; MIDDLE AGED; NITRILES; ODDS RATIO; POSTMENOPAUSE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; TRIAZOLES; UNITED STATES;

EID: 78651093475     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0952-6     Document Type: Article

References (36)

1. A Jemal R Siegel E Ward, et al. 2009 Cancer statistics, 2009 CA Cancer J Clin 59 25 49 10.3322/caac.20006
2. RT Chlebowski 2008 Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-positive early breast cancer Breast Cancer Res Treat 112 25 34 1:CAS:528:DC%2BD1MXjtVyjsr4%3D 10.1007/s10549-008-0237-5 19101792
3. EP Winer C Hudis HJ Burstein, et al. 2005 American Society of Clinical Oncology Clinical Technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004 J Clin Oncol 23 1 11 10.1200/JCO.2005.01.005 (Pubitemid 46211411)
4. A Goldhirsch JN Ingle RD Gelber, et al. 2009 Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy for early breast cancer 2009 Ann Oncol 20 8 1319 1329 1:STN:280:DC%2BD1Mrjtlyhug%3D%3D 10.1093/annonc/mdp322 19535820
5. RW Charlson E Brown HJ Burstein, et al. 2006 NCCN Task Force Report: adjuvant therapy for breast cancer J Natl Compr Cancer Netw 4 Suppl 1 S1 S26
6. R Sainsbury 2004 Aromatase inhibitors in the treatment of advance breast cancer: is there a relationship between potency and clinical efficacy? Br J Cancer 90 1733 1739 1:CAS:528:DC%2BD2cXkvFWltb4%3D 15150604
7. LJ Gibson CK Dawson DH Lawrence, et al. 2007 Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women Cochrane Database Syst Rev 24 1 CD003370
8. L Osterberg T Blaschke 2005 Adherence to medication NEJM 353 487 497 1:CAS:528:DC%2BD2MXntVCisL0%3D 10.1056/NEJMra050100 16079372 (Pubitemid 41127293)
9. SH Simpson DT Eurich SR Majumdar, et al. 2006 A meta-analysis of the association between adherence to drug therapy and mortality BMJ 333 15 20 10.1136/bmj.38875.675486.55 16790458
10. RT Chlebowski ML Geller 2006 Adherence to endocrine therapy for breast cancer Oncology 71 1 9 1:CAS:528:DC%2BD2sXktFemt7o%3D 17344666
11. C Owusu DSM Buist TS Field, et al. 2008 Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer J Clin Oncol 26 549 555 10.1200/JCO.2006.10.1022 18071188 (Pubitemid 351264347)
12. AH Patridge PS Wang PS Winer, et al. 2003 Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer J Clin Oncol 21 602 606 10.1200/JCO.2003.07.071 (Pubitemid 46621892)
13. AH Partridge A LaFountain E Mayer BS Taylor E Winer A Asnis-Alibozek 2008 Adherence to initial adjuvant anastrozole therapy among women with early-stage cancer J Clin Oncol 26 4 523 526 10.1200/JCO.2007.11.5451 (Pubitemid 351264348)
14. L Atkins L Fallowfield 2006 Intentional and non-intentional non-adherence to medication amongst breast cancer patients Eur J Cancer 42 2271 2276 10.1016/j.ejca.2006.03.004 16644208 (Pubitemid 44307611)
15. KL Kahn EC Schneider JL Malin, et al. 2007 Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use Med Care 45 431 439 10.1097/01.mlr.0000257193.10760.7f 17446829
16. TL Lash MP Fox JL Westrup, et al. 2006 Adherence to tamoxifen over the five-year course Breast Cancer Res Treat 99 215 220 10.1007/s10549-006-9193-0 16541307 (Pubitemid 44268270)
17. S Demissie RA Silliman TL Lash 2001 Adjuvant tamoxifen: predictors of use, side-effects and discontinuation in older women J Clin Oncol 19 322 328 1:CAS:528:DC%2BD3MXhtVektrk%3D 11208822
18. V Ziller M Kalder US Alberts, et al. 2009 Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer Ann Oncol 20 431 436 1:STN:280:DC%2BD1M7mvVynsA%3D%3D 10.1093/annonc/mdn646 19150950
19. United States Department of Health and Human Service Office of Human Protections (OHRP) (2009) http://www.hhs.gov/ohrp/humansubjects/guidance/ 45cfr46.htm#46.101. Accessed 9 December 2009
20. M Charlson TP Szatrowski J Peterson, et al. 1994 Validation of a combined comorbidity index J Clin Epidemiol 47 11 1245 1251 1:STN:280: DyaK2M3jvFantQ%3D%3D 10.1016/0895-4356(94)90129-5 7722560 (Pubitemid 24361532)
21. PJ Goodwin M Ennis KI Pritchard, et al. 1999 Risk of menopause during the first year after breast cancer diagnosis J Clin Oncol 17 2365 2370 1:STN:280:DC%2BD3c%2FjtVShtQ%3D%3D 10561298
22. JA Petrek MJ Naughton LD Case, et al. 2006 Incidence, time course, and determinates of menstrual bleeding after breast cancer treatment: a prospective study J Clin Oncol 24 1045 1051 10.1200/JCO.2005.03.3969 16476708 (Pubitemid 46638800)
23. A Partridge S Gelber RD Gelber, et al. 2007 Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI Eur J Cancer 43 1646 1653 10.1016/j.ejca.2007.04.006 17512721 (Pubitemid 47042368)
24. PA Ganz GA Greendale L Petersen, et al. 2003 Breast cancer in younger women: reproductive and late health effects of treatment J Clin Oncol 21 4184 4193 10.1200/JCO.2003.04.196 14615446 (Pubitemid 46606187)
25. DP Goldman GF Joyce Y Zheng 2007 Prescription drug cost sharing: associations with medication and medical utilization and spending and health JAMA 298 1 61 69 1:CAS:528:DC%2BD2sXovF2rs78%3D 10.1001/jama.298.1.61 17609491 (Pubitemid 47026771)
26. BR Motheral SM Heinle 2004 Predictors of satisfaction of health plan members with prescription drug benefits Am J Health Syst Pharm 61 10 1007 1014 15160776
27. MC Sokol KA McGuigan RR Verbrugge, et al. 2005 Impact of medication adherence on hospitalization risk and healthcare cost Med Care 43 521 530 10.1097/01.mlr.0000163641.86870.af 15908846 (Pubitemid 40847288)
28. TB Gibson TL Mark K Axelsen, et al. 2006 Impact of statin copayments on adherence and medical care utilization and expenditures Am J Manag Care 12 SP11 SP19 17173486
29. R Horne J Weinman 1999 Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness J Psychosom Res 47 555 567 1:STN:280:DC%2BD3c7isFantw%3D%3D 10.1016/S0022-3999(99)00057-4 10661603 (Pubitemid 30029305)
30. EA Grunfeld MS Hunter P Sikka, et al. 2005 Adherence beliefs among breast cancer patients taking tamoxifen Patient Educ Couns 59 97 102 10.1016/j.pec.2004.10.005 16198223 (Pubitemid 41399883)
31. AP Turner DR Kivlahan AP Sloan, et al. 2007 Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health belief model Mult Scler 13 1146 1152 1:STN:280:DC%2BD2snktlKitg%3D%3D 10.1177/1352458507078911 17967842 (Pubitemid 351541418)
32. RC Coombes E Hall LJ Gibson, et al. 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer NEJM 350 1081 1092 1:CAS:528:DC%2BD2cXitV2qtbc%3D 10.1056/NEJMoa040331 15014181 (Pubitemid 38298988)
33. A Howell J Cuzick M Baum, et al. 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone, or in Combination) trial after completion of 5-years' adjuvant treatment for breast cancer Lancet 365 60 62 1:STN:280:DC%2BD2M%2FhsVartA%3D%3D 10.1016/S0140-6736(05)74803-0 15639680
34. J Yoon JL Malin ML Tao, et al. 2008 Symptoms after breast cancer treatment: are they influenced by patient characteristics? Breast Cancer Res Treat 108 153 165 10.1007/s10549-007-9599-3 17492377 (Pubitemid 351311365)
35. LS Schwartzberg P Cobb F Senecal, et al. 2009 Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer Breast 18 78 83 10.1016/j.breast.2009.01.002 19342237
36. T Delate DE Mager J Sheth, et al. 2005 Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population Am J Manag Care 11 29 36 15697098